Metastatic Breast Cancer
Conference Coverage
Expanding the role of PARP inhibitors in breast cancer
Conference Coverage
Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastases
Conference Coverage
Pembrolizumab plus chemo shows benefits for PD-L1–rich triple-negative breast cancer
Patients with triple-negative breast cancers with PD-L1 combined positive score higher than 10 had better progression-free survival with...
Conference Coverage
LOTUS: Ipatasertib plus paclitaxel may prolong OS in TNBC
Ipatasertib provided a “clinically meaningful,” but not statistically significant, 9-month improvement in median overall survival.
From the Journals
Mammography cuts risk for fatal breast cancers: New data
A large study showed a survival benefit from mammography, but an expert questioned the study’s methodology.
Conference Coverage
Novel immune activator boosts immunotherapy benefit in TNBC
Conference Coverage
EMBRACA shows no overall survival benefit with talazoparib
Talazoparib did not confer an overall survival benefit over chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast...
Conference Coverage
Metastatic cancer linked to worse outcomes of COVID-19
Guidelines
ESMO gets creative with guidelines for breast cancer care in the COVID-19 era
News from the FDA/CDC
FDA OKs new drug for triple-negative breast cancer
Sacituzumab govitecan-hziy (Trodelvy) is now approved for adults with metastatic triple-negative breast cancer who received at least two prior...
News from the FDA/CDC
FDA approves first new breast cancer drug with international group